CN108272795A - A kind of application of monascin in preparing treatment and delaying osteoarthritis drugs - Google Patents
A kind of application of monascin in preparing treatment and delaying osteoarthritis drugs Download PDFInfo
- Publication number
- CN108272795A CN108272795A CN201810122371.5A CN201810122371A CN108272795A CN 108272795 A CN108272795 A CN 108272795A CN 201810122371 A CN201810122371 A CN 201810122371A CN 108272795 A CN108272795 A CN 108272795A
- Authority
- CN
- China
- Prior art keywords
- monascin
- application
- drug
- osteoarthritis
- delaying
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
It is an object of the present invention to provide a kind of application of monascin in preparing treatment and delaying osteoarthritis lesion drug.The side effect larger compared to Western medicine, monascin, can more leniently relief from osteoarthritis lesions as a kind of food extracts.
Description
Technical field
The present invention relates to a kind of application of monascin, more particularly to monascin is used to prepare treatment and delays Bones and joints
Application in scorching drug.
Background technology
Osteoarthritis is most common knee joint degenerative disease, is apt to occur in 50 years old or more crowd.Clinical manifestation arthritis
Bitterly, stiff, especially for a long time after activity, the quality of life of the different degrees of influence middle-older patient of this disease.But it is at present
Only, clinical treatment is based on non-steroidal drug and replacement knee in arthroplasty.Non-steroidal drug can only improve the remission of disease
Pain cannot reverse osteoarthritis progression, and there is also costly postoperative infection equivalent risks for knee prosthesis.
Osteoarthritis can be caused by many factors, such as abnormal stress, local nutritional deficiency and congenital gene unconventionality,
Middle inflammation is one of most important pathogenic mechanism of osteoarthritis.By inflammatory factor mediate cartilage cell's dysfunction be considered as
An important ring in osteoarthritis retrogression pathological changes process, therefore may for the research of inflammation mediated cartilage cell's dysfunction
It is the important channel for treating osteoarthritis.
Red rice is product of the rice after Fermentation Condition of Monascus spp, has been had go through within more than 1000 years as food and nutriment
History.Monascin (Monascin) is a kind of pigment extract of red rice.Monascin is shown in multinomial pharmaceutical research
Good bioactivity, such as antitumor, immunosupress, septicopyemia disease etc..But its to osteoarthritis disorders whether
It is unclear with therapeutic effect.
Invention content
It is an object of the present invention to provide a kind of application of monascin in preparing treatment and delaying osteoarthritis lesion drug.
The side effect larger compared to Western medicine, monascin, can more leniently relief from osteoarthritis diseases as a kind of food extracts
Become.
The technical solution adopted by the present invention is:
The present invention provides a kind of application of monascin in preparing treatment and delaying osteoarthritis drugs, the monascus
Plain molecular structural formula is shown in formula (I):
Further, the drug further includes pharmaceutical carrier, and the pharmaceutical carrier is micro emulsion, nano liposomes etc..
Further, the drug is tablet, emulsion or capsule etc..
Further, the drug is compound formulation, including erythromycin and is selected from polycaprolactone, the poly- second of polylactic acid-two
Alcohol or polyvinyl alcohol contain material.
Further, the monascin dosage of the drug is 5-10mg/kg weight.
Compared with prior art, advantageous effect of the present invention is mainly reflected in:Monascin having good life as a kind of
The active food extract of object has dosage low, the apparent feature of antiphlogistic effects.
Description of the drawings
Fig. 1:Therapeutic effect of the monascin to mouse medial meniscus of knee joint excision buckling form (DMM).Sham is
Sham-operation group, DMM are osteoarthritis group, and DMM+Ms is osteoarthritis+monascin group.A:X-ray Imageology.B:SO is dyed
(proteoglycans and glycosaminoglycan dyeing) Histological change.C:Histological score.
Fig. 2:The CCK8 toxicity trial compares figures of monascin.
Fig. 3:QPCR, ELISA and Western that monascin influences cartilage cell's inflammatory parameters in alleviation IL-1 β
Blot experimental control figures;A is expressions of the iNOS and COX-2 in mRNA level in-site;B is TNF-α and IL-6 in mRNA level in-site
Expression;C is expressions of the iNOS and COX-2 in protein level;D is iNOS and COX-2 gray value ratio statistical charts;E
It is PGE2 and Nitrite in extracellular expression;F is TNF-α and IL-6 in extracellular expression.
Fig. 4:For cartilage cell under IL-1 β stimulations, monascin improves the compares figure of its extracellular matrix complex functionality;A
For II Collagen Type VIs (Collagen II), proteoglycans (Aggrecan), MMP13, ADAMTS-5 protein level expression feelings
Condition;B is Collagen II, Aggrecan, MMP13, ADAMTS-5 gray value ratio statistical chart;C is II Collagen Type VIs
The expression fluorogram of (Collagen II) in protein level;D is II Collagen Type VIs (Collagen II) in the expression of protein level
Fluorescent value ratio statistical chart.
Fig. 5:Cartilage cell is under IL-1 β stimulations, Western blot experimental control of the monascin to its NF- κ B access
Figure;A is expression of the NF- κ B signals accesses in protein level;B is the cellular immunofluorescence experimental control that p65 enters core situation;
C is the statistical chart of p65 and Lamin B gray value ratios;D is the statistical chart of I κ B α and GAPDH gray value ratios.
Specific implementation mode
With reference to specific embodiment, the present invention is described further, but protection scope of the present invention is not limited in
This:
Embodiment 1
1, experimental procedure:
(1) modeling method:Take C57BL/6 Male wild-types (WT) mouse of 60 10 week old.Pass through medial meniscus
(DMM) operation goes to stablize inducing mouse osteoarthritis.Peritoneal injection 2% (w/v) amobarbital (40mg/kg) is anaesthetized
Afterwards, then iodophor disinfection cuts right capsula articularis genus on the inside of kneecap tendon, medial meniscus ligament is cut off with microsurgery scissors.
Mouse is randomly divided into sham-operation group, physiological saline group and monascin treatment group.After DMM, monascin administration group
(10mg/kg/ days;Continuous 8 weeks once a day by applying the monascin being dissolved in CMC in stomach).Meanwhile it is small in vehicle group
Mouse is administered the CMC of equivalent.All animals are condemned to death after eight weeks after surgery, collect cartilaginous tissue sample and are penetrated for histology X
Line analysis.
(2) Primary mouse cultured chondrocytes:With ten immature C57BL/6 mouse (5 of excessive yellow Jackets pair
Only male and 5 females, 10 days) sentence euthanasia.The knee of mouse is aseptically carefully collected by disecting microscope
Cartilage, and at 37 DEG C tissue is handled with 2mg/ml (0.1%) clostridiopetidase As II 4 hours.The cartilaginous tissue inoculation that digestion is suspended
Into tissue culture medium.Cultured chondrocytes are containing 10% fetal calf serum (FBS;Hyclone, Thermo Scientifc,
Logan, UT, USA) and 1% penicillin/streptomycin antibiotic (Gibco, Invitrogen, Grand) DMEM/F12
In (Gibco, Invitrogen, Grand Island, NY), 5% carbon dioxide, 37 DEG C of incubator.After cultivating 24 hours more
Change culture medium.When up to 80% to 90% degree of cross linking, by using 0.25% trypsase-EDTA (Gibco,
Invitrogen cell) is harvested.Then, cell is implanted into density appropriate in 10cm culture dishes again.Second generation cartilage is thin
Born of the same parents are used for our all experiments, because passing on for 0 generation to significant variation is not observed during 2 generations.Cartilage cell is 5%
CO2, in culture in the incubator of 37 DEG C of conditions, complete medium is every other day replaced once.
(3) CCK8 methods measure drug cytotoxicity and drug antiphlogistic effects:CCK8 methods measure drug cytotoxicity:By
Two generation cartilage cells are transferred in 96 orifice plates (50000cells/cm2), and in the monascin of various concentration (5,10,15,30 μ
M it is incubated 24 hours and 48 hours in).At the appointed time, cell is washed with phosphate buffered saline (PBS), then contains 100 μ l
There is the DMEM/F12 of 10 μ lCCK-8 to be added in each hole of tablet, and is incubated again 2 hours at a temperature of 37 DEG C.Then it uses
The absorbance of spectrophotometer measured hole at 450nm.
(4) cartilage cell of step (2) is divided into 5 groups, and group 1,2 is control group (with 100% DMEM/F12 basal mediums
For control), 35 μm of monascin+DMEM/F12 basal mediums of addition of group, 4 10 μm of monascin+DMEM/F12 bases of addition of group
Basal culture medium, 4 15 μm of monascin+DMEM/F12 basal mediums of addition of group, after 37 DEG C of cultures for 24 hours, group 2, group 3, group 4 abandon training
IL-1 β+DMEM/F12 the basal mediums of final concentration 10ng/ml are separately added into after foster base again, after 37 DEG C act on 24 hours, are collected
Supernatant detects to the ELISA of inflammatory factor, and cell precipitation separation cell protein and cell RNA carry out Western respectively
ELISA is used in combination to detect the expression situation of change of cartilage cell's its endocellular function albumen under inflammatory stimulus in blot and qPCR
The case where detecting cell secretion inflammatory factor.
(5)Western blots:The cell precipitation RIPA method leach proteins after step (4) effect for 24 hours are taken, BCA methods are used in combination
Survey albumen concentration.It takes protein extract that Loading buffer and water is added, makes the quantification of 30 μ g of protein content, 100 DEG C of heating
5min makes albuminous degeneration.The protein liquid after 20 μ l denaturation, PAGE gel electricity are added in each hole of PAGE gel
Transferring film to pvdf membrane, 5% skimmed milk power room temperature closes 2h, primary antibody (primary antibody: primary antibody dilution volume ratio=1: 1000) 4 DEG C after swimming
Overnight, TBST washs pvdf membrane 5min × 4 time, and secondary antibody (secondary antibody: volume ratio=1 TBST: 1000) is incubated at room temperature 2h, TBST washings
5min × 4 time, the development of ECL systems.GAPDH takes purpose band to inhale as internal reference, Image lab 3.0 pick-up slip band gray values
Luminosity is with internal reference band ratio as relative expression quantity.Anti- p65, I κ B α primary antibodies are purchased in Cell Signaling
Technology, Inc. (Beverly, MA, USA), anti-mm P-13, ADAMTS-5, iNOS, COX-2 primary antibody are purchased in Santa
Cruz Biotechnology (Santa Cruz, CA, USA), anti-collagen-II and aggrecan primary antibodies are purchased in Abcam
(Cambridge, MA, USA).Secondary antibody is purchased in Santa Cruz Biotechnology (Santa Cruz, CA, USA).
(6) real-time fluorescence quantitative PCR:It takes the cell precipitation after step (4) effect for 24 hours to carry RNA with Trizol methods, and measures
Concentration.Reverse transcription is carried out with PrimeScriptTM Reverse Transcriptase kits, is tested with SYBR (Shanghai life work) kit, and
And statistical data, carry out differential expression analysis.
Target gene primer sequence:
COX-2 (F), SEQ ID NO.1:5’-TCCTCACATCCCTGAGAACC-3’;
COX-2 (R), SEQ ID NO.2:5’-GTCGCACACTCTGTTGTGCT-3’;
INOS (F), SEQ ID NO.3:5’-GACGAGACGGATAGGCAGAG-3’;
INOS (R), SEQ ID NO.4:5’-CACATGCAAGGAAGGGAACT-3’;
IL-6 (F), SEQ ID NO.5:5’-CCGGAGAGGAGACTTCACAG-3’;
IL-6 (R), SEQ ID NO.6:5’-TCCACGATTTCCCAGAGAAC-3’;
TNF-α (F), SEQ ID NO.7:5’-ACGGCATGGATCTCAAAGAC-3’;
TNF-α (R), SEQ ID NO.8:5’-GTGGGTGAGGAGCACGTAGT-3’.
(7) ELISA detects the cellular inflammation factor:Step (4) is taken to act on the supernatant obtained afterwards for 24 hours, according to kit (R&
D Systems, Inc., Minneapolis, MN, USA) operating procedure addition reagent, it is used in combination microplate reader to detect absorbance.
(8) cellular immunofluorescence:Cell precipitation after step (4) effect for 24 hours is seeded in 6 orifice plates slide, passes through cell
Immunofluorescence test each group (packet synchronization is rapid (the 4)) expression of collagen II and the intracellular targeting situation of p65.With
PBS is washed 5 minutes × 3 times, then is fixed with 4% paraformaldehyde.0.5% TRITON is added after washing 5min × 3 time with PBS
X-100 handles 10min.5min × 3 time are washed with PBS, then 30min is closed with 5% BSA.Blot PBS, be added dropwise p65 (1:
200, CST) and II Collagen Type VIs antibody (1: 200, Abcam), 4 DEG C overnight.Next day is used after PBS washs 5min × 3 time with cell
Green fluorescence secondary antibody (1: 400, Bioworld) room temperature, which is protected from light, is incubated 1h.After being washed with PBS, then with DAPI contaminate core.It is washed again with PBS
After washing 5min × 3 time, anti-fluorescence quenching, mounting is added dropwise.Slide is taken in fluorescence microscopy microscopic observation and is shot.
2, experimental result:
(1) x-ray of simple Bones and joints group (DMM in Fig. 1) shows that joint space obviously narrows, articular surface calcification.And it is red
After aspergillus extract for treating (DMM+Ms in Fig. 1), articular surface and joint space improve significantly relative to DMM groups, it was demonstrated that red yeast rice
Mycin can significantly delay the progress (Fig. 1) of osteoarthritis.
(2) after obtaining absorbance by CCK8 experiments, we count the ratio of each group absorbance/control group absorbance, knot
Fruit shows under 5,10,15,30 μm of monascin effects that interior cartilage cell's light absorption value and 0nN groups (no monascin group) nothing are aobvious for 24 hours
Significant difference is write, shows 5,10,15,30 μm of monascins to cell without notable toxicity;And 30 μm of monascin groups are soft after 48h
Osteocyte light absorption value is substantially less than 0nM groups, shows that 30 μm of monascin effect 48h have certain cartilage cell's toxicity.Pass through
This experiment, it is determined that monascin is to the safe concentration of cartilage cell, i.e. 0~15 μm (Fig. 2).
(3) it is tested by Western blot, qPCR and ELISA, monascin can reduce soft under IL-1 β stimulations
The content of the osteocyte cellular inflammation factor, it was confirmed that monascin has anti-inflammatory effect (Fig. 3) really.
(4) by Western blot, immunofluorescent test, show that monascin can reduce the inflammatory of extracellular matrix
It degrades (Fig. 4).
(5) pass through further protein blot analysis of experiments, it has been found that monascin can be by inhibiting NF- κ B signals logical
Anti-inflammatory effect (Fig. 5) is played in the activation on road, this result is also able to verification (Fig. 5) in the experiment of the cellular immunofluorescence of p65.
In addition, monascin of the present embodiment as known structure, it can be directly from market purchasing or chemical synthesis, containing red
The pharmaceutical composition of aspergillin can be some long-acting or local sustained release preparations, for example, some of modern medicine can be utilized
Biomaterial, including polycaprolactone, polylactic acid-polyglycol, polyvinyl alcohol etc. contain monascin, form compound system
Agent.
SEQUENCE LISTING
<110>Attached second hospital of Wenzhou Medical University, attached Yu Ying children's hospitals of Wenzhou Medical University
<120>A kind of application of monascin in preparing treatment and delaying osteoarthritis drugs
<130> 2018
<160> 8
<170> PatentIn version 3.5
<210> 1
<211> 20
<212> DNA
<213>It is artificial synthesized
<400> 1
tcctcacatc cctgagaacc 20
<210> 2
<211> 20
<212> DNA
<213>It is artificial synthesized
<400> 2
gtcgcacact ctgttgtgct 20
<210> 3
<211> 20
<212> DNA
<213>It is artificial synthesized
<400> 3
gacgagacgg ataggcagag 20
<210> 4
<211> 20
<212> DNA
<213>It is artificial synthesized
<400> 4
cacatgcaag gaagggaact 20
<210> 5
<211> 20
<212> DNA
<213>It is artificial synthesized
<400> 5
ccggagagga gacttcacag 20
<210> 6
<211> 20
<212> DNA
<213>It is artificial synthesized
<400> 6
tccacgattt cccagagaac 20
<210> 7
<211> 20
<212> DNA
<213>It is artificial synthesized
<400> 7
acggcatgga tctcaaagac 20
<210> 8
<211> 20
<212> DNA
<213>It is artificial synthesized
<400> 8
gtgggtgagg agcacgtagt 20
Claims (5)
1. a kind of application of monascin in preparing treatment and delaying osteoarthritis drugs, the monascin molecular structural formula
For shown in formula (I):
2. application as described in claim 1, which is characterized in that the drug further includes pharmaceutical carrier, the pharmaceutical carrier choosing
From micro emulsion and nano liposomes.
3. application as described in claim 1, which is characterized in that the drug is compound formulation, including erythromycin and is selected from
Polycaprolactone, polylactic acid-polyglycol or polyvinyl alcohol contain material.
4. application as described in claim 1, which is characterized in that the dosage form of the drug is tablet, emulsion or capsule.
5. application according to any one of claims 1-4, which is characterized in that the erythromycin dosage of the drug is 5-10mg/
Kg weight.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810122371.5A CN108272795A (en) | 2018-01-30 | 2018-01-30 | A kind of application of monascin in preparing treatment and delaying osteoarthritis drugs |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810122371.5A CN108272795A (en) | 2018-01-30 | 2018-01-30 | A kind of application of monascin in preparing treatment and delaying osteoarthritis drugs |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108272795A true CN108272795A (en) | 2018-07-13 |
Family
ID=62807879
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810122371.5A Pending CN108272795A (en) | 2018-01-30 | 2018-01-30 | A kind of application of monascin in preparing treatment and delaying osteoarthritis drugs |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108272795A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108720007A (en) * | 2018-08-29 | 2018-11-02 | 武汉轻工大学 | A kind of functional Monascus liposome and preparation method thereof containing Lovastatin |
-
2018
- 2018-01-30 CN CN201810122371.5A patent/CN108272795A/en active Pending
Non-Patent Citations (2)
Title |
---|
WEI-HSUAN HSU, ET AL.: "Monascus-fermented metabolite monascin suppresses inflammation via PPAR-c regulation and JNK inactivation in THP-1 monocytes", 《FOOD AND CHEMICAL TOXICOLOGY》 * |
付钰: "中药大血藤对佐剂性关节炎大鼠血清TNF - α、IL - 6的影响", 《现代医院》 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108720007A (en) * | 2018-08-29 | 2018-11-02 | 武汉轻工大学 | A kind of functional Monascus liposome and preparation method thereof containing Lovastatin |
CN108720007B (en) * | 2018-08-29 | 2021-10-22 | 武汉轻工大学 | Lovastatin-containing functional red yeast rice liposome and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104072584B (en) | Peptides for promoting angiogenesis and a use thereof | |
CN106456658A (en) | Compositions of selenoorganic compounds and methods of use thereof | |
CN107531768A (en) | Anti-senescence compounds and application thereof | |
CN102427814A (en) | Kinase protein binding inhibitors | |
Buss et al. | Efficacy and safety of mitomycin C as an agent to treat corneal scarring in horses using an in vitro model | |
US20210205372A1 (en) | Method and Composition for Promoting Cell Growth and Tissue Repair | |
CN104321064A (en) | Chondroitin for use in medicine | |
RU2473353C1 (en) | Composition for preventing and treating cancer containing agg albumen with copper vitriol | |
WO2015190872A1 (en) | Pharmaceutical composition containing spirulina maxima extract as active ingredient for treating and preventing obesity | |
CN109715191A (en) | Pharmaceutical associations for the conversion of neoplastic cells into non-neoplastic cells and uses thereof | |
CN108272795A (en) | A kind of application of monascin in preparing treatment and delaying osteoarthritis drugs | |
CN109125329A (en) | The new application of 1 class Niemann-Pick protein inhibitor of c-type | |
CN108685892A (en) | Purposes of the chlorogenic acid and combinations thereof in the drug for preparing treatment squamous cell carcinoma | |
RU2638285C1 (en) | Method for estimation of effectiveness of impact of chemotherapeutic precautions of xenograft model in vivo | |
CN108704139A (en) | A kind for the treatment of of pancreatic cancer pharmaceutical composition with synergy | |
KR102152659B1 (en) | A composition for inhibiting cancer metastasis comprising tonsil-derived mesenchymal stem cell conditioned medium | |
CN106974915A (en) | A kind of application of Celastrol in preparing treatment and delaying intervertebral disk retrogression lesion medicine | |
CN114042064A (en) | Application of nitazoxanide in pharmacy | |
CN107012207A (en) | LRP5 is used as clinical diagnosis and the application of suppression digestive system tumor | |
CN108853081B (en) | Application of amentoflavone in preparation of medicine for treating necrotic enteritis of chicken | |
Cao et al. | Receptor tyrosine kinase C-kit promotes a destructive phenotype of FLS in osteoarthritis via intracellular EMT signaling | |
CN105412089A (en) | Application of compound VS1 in preparation of anti-non-small cell lung cancer medicine | |
CN108606969A (en) | Aspirin is preparing the application in treating intervertebral disc degeneration drug | |
CN109223801A (en) | A kind of new the killing agent of gastric cancer tumor stem cell and its application | |
CN109744199A (en) | A kind of tumour cell heterograft zebra fish model, its construction method and application |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20180713 |
|
WD01 | Invention patent application deemed withdrawn after publication |